Sanofi (SNY) Non-Current Receivables (2018 - 2025)
Sanofi's Non-Current Receivables history spans 8 years, with the latest figure at $640.2 million for Q4 2025.
- On a quarterly basis, Non-Current Receivables rose 6.99% to $640.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $640.2 million, a 6.99% increase, with the full-year FY2025 number at $640.2 million, up 6.99% from a year prior.
- Non-Current Receivables hit $640.2 million in Q4 2025 for Sanofi, up from $598.4 million in the prior quarter.
- Over the last five years, Non-Current Receivables for SNY hit a ceiling of $640.2 million in Q4 2025 and a floor of $200.2 million in Q4 2021.
- Historically, Non-Current Receivables has averaged $377.6 million across 5 years, with a median of $246.9 million in 2022.
- Biggest five-year swings in Non-Current Receivables: plummeted 32.3% in 2021 and later soared 195.84% in 2024.
- Tracing SNY's Non-Current Receivables over 5 years: stood at $200.2 million in 2021, then rose by 23.33% to $246.9 million in 2022, then dropped by 18.07% to $202.3 million in 2023, then skyrocketed by 195.84% to $598.4 million in 2024, then rose by 6.99% to $640.2 million in 2025.
- Business Quant data shows Non-Current Receivables for SNY at $640.2 million in Q4 2025, $598.4 million in Q4 2024, and $202.3 million in Q4 2023.